This handbook provides up-to-date and comprehensive treatment of all plasma cell disorders, including both common and rare disorders. All disease aspects from pathogenesis to most recent therapy are covered. The text originates from the Mayo Clinic, the world's most experienced institution in plasma cell disorders.
Comprehensive treatise on all plasma cell disorders from the gene level to treatment of emergencies
Chapters are uniformly organized for easy data access
All authors are important authorities in their field with extensive clinical experience
This handbook provides up-to-date and comprehensive treatment of all plasma cell disorders, including both common and rare disorders. All disease a...
After a decade of tremendous progress in the diagnostic and therapeutic approaches to malignant lymphoma, optimal treatment strategies are now based not only on accurate diagnosis but also on thorough evaluation of clinical and molecular risk factors. Even more importantly, molecular targeted approaches have been shown to be effective in the treatment of distinct lymphoma subtypes. Against this background, clinical management of especially the rare lymphomas remains a challenge for the general oncologist. This book provides a comprehensive overview of current treatment strategies in these...
After a decade of tremendous progress in the diagnostic and therapeutic approaches to malignant lymphoma, optimal treatment strategies are now based n...
This handbook provides up-to-date and comprehensive treatment of all plasma cell disorders, including both common and rare disorders. All disease aspects from pathogenesis to most recent therapy are covered. The text originates from the Mayo Clinic, the world's most experienced institution in plasma cell disorders.
Comprehensive treatise on all plasma cell disorders from the gene level to treatment of emergencies
Chapters are uniformly organized for easy data access
All authors are important authorities in their field with extensive clinical experience
This handbook provides up-to-date and comprehensive treatment of all plasma cell disorders, including both common and rare disorders. All disease a...
This book is a comprehensive source of up-to-date information on plasma cell neoplasms. Key features include the provision of new criteria for the diagnosis of symptomatic multiple myeloma requiring treatment and the description of novel therapies for myeloma and other plasma cell neoplasms that have only very recently been licensed by the U.S. Food and Drug Administration. Examples include lenalidomide as first-line therapy, panobinostat in combination with bortezomib plus dexamethasone for relapsed/refractory myeloma, ibrutinib for Waldenstrom s macroglobulinemia, and new therapeutic...
This book is a comprehensive source of up-to-date information on plasma cell neoplasms. Key features include the provision of new criteria for the ...
The diagnosis of myelodysplastic syndromes (MDS), a heterogeneous group of clonal hematopoietic disorders, is being made with increasing frequency over the past decade owing to increased recognition, improved understanding, and an aging population. This book, completely updated since the first edition, summarizes in a concise and focused way the current knowledge of all aspects of MDS. Clinical presentation, etiology, epidemiology, molecular biology, classification, and staging are all discussed. Clear guidance is provided on diagnosis and differential diagnosis, and treatment...
The diagnosis of myelodysplastic syndromes (MDS), a heterogeneous group of clonal hematopoietic disorders, is being made with increasing frequen...
Better therapy of acute leukemias depends ultimately on better understanding of the distinction between leukemic and normal progenitor cells. Thus, several chapters in this volume describe current knowledge of acute leukemia biology and discuss new classification systems that have arisen consequent to emerging insights into pathogenesis. Treatment has also improved for particular types of acute leukemia. Given our intention that the book be useful to clinicians, we pay particular attention to these advances, to management of acute leukemia in general, and to development of new...
Better therapy of acute leukemias depends ultimately on better understanding of the distinction between leukemic and normal progenitor cells. Thus,...
After a decade of tremendous progress in the diagnostic and therapeutic approaches to malignant lymphoma, optimal treatment strategies are now based not only on accurate diagnosis but also on thorough evaluation of clinical and molecular risk factors.
After a decade of tremendous progress in the diagnostic and therapeutic approaches to malignant lymphoma, optimal treatment strategies are now based n...
The diagnosis of myelodysplastic syndromes (MDS), a heterogeneous group of clonal hematopoietic disorders, is being made with increasing frequency over the past decade owing to increased recognition, improved understanding, and an aging population. This book, completely updated since the first edition, summarizes in a concise and focused way the current knowledge of all aspects of MDS. Clinical presentation, etiology, epidemiology, molecular biology, classification, and staging are all discussed. Clear guidance is provided on diagnosis and differential diagnosis, and treatment...
The diagnosis of myelodysplastic syndromes (MDS), a heterogeneous group of clonal hematopoietic disorders, is being made with increasing frequen...
This book examines in detail the current treatment options for first-line, relapsed, and refractory Hodgkin lymphoma and the management appropriate in special clinical circumstances, including in the elderly, pregnant women, and those with lymphocyte-predominant disease.
This book examines in detail the current treatment options for first-line, relapsed, and refractory Hodgkin lymphoma and the management appropriate in...
The diversity of MDS gives rise to challenges in diagnosis and clinical decision making, and the highly variable clinical course necessitates a risk-adapted treatment strategy and the application of disease-specific therapies.
The diversity of MDS gives rise to challenges in diagnosis and clinical decision making, and the highly variable clinical course necessitates a risk-a...
